At the 2026 ATS International Conference in Orlando, Florida, research underscored the relentless surge of rapidly progressive silicosis among engineered stone countertop fabricators. With lung transplantation remaining the only terminal option, the urgency for therapeutic intervention is critical.
Translational studies identified new molecular targets. Miao et al. showed that inhibiting histone deacetylase 6 (HDAC6) reduced alveolar macrophage activity and collagen deposition in mice. Liebler et al. utilized human precision cut lung slices (PCLS) to demonstrate that silica exposure directly increases mesenchymal markers of fibrosis, including α-SMA and vimentin. Furthermore, Hussein et al. used spatial transcriptomics to identify unique osteoclast-like macrophage phenotypes driving granuloma formation in engineered stone fabricators.
Clinical reports highlighted dangerous atypical manifestations. Castillo-Morales et al. and Moyer et al. documented silicosis patients presenting with concomitant fungal infections, including aspergillosis and cryptococcosis, theorized to result from impaired alveolar macrophage function. Karakaya et al. warned of cases presenting with isolated lymph node involvement, closely mimicking sarcoidosis or lymphoma, making occupational history vital to avoid misdiagnosis. A UCLA cohort study by Saggar et al. also revealed a 100% prevalence of precapillary pulmonary hypertension in stone fabricators referred for transplant, far exceeding rates in idiopathic pulmonary fibrosis.
Advances in surveillance are underway. The National Institute for Occupational Safety and Health emphasized the foundational role of ILO-certified B readers and the emerging potential of artificial intelligence to enhance chest radiograph screening efficiency.